Obesity drugs spark debate over access and stigma worldwide

Experts in the United States highlighted that next‑generation GLP‑1 obesity drugs are becoming more available but remain costly, limiting access for many patients. A panel at a health‑journalism conference urged clinicians to use language that reduces weight stigma, recommending the term “people with obesity” and emphasizing that these medicines can improve long‑term health beyond weight loss. The Centers for Medicare & Medicaid Services plan to pilot temporary coverage of GLP‑1s with a modest co‑pay, potentially expanding access for beneficiaries.

In South Africa, health officials noted that nearly half of adults are overweight or obese, with women disproportionately affected. The rise of GLP‑1 injections has renewed public discussion about distinguishing medical obesity from excess weight, stressing that obesity carries serious risks such as diabetes, hypertension and heart disease. Officials warned that misconceptions about personal responsibility persist, and they highlighted the need for medical supervision when using weight‑loss injections.

Both regions underscore the broader challenge of ensuring equitable access to effective obesity treatments while combating persistent weight‑related bias.